Open AccessP06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC‐1 STUDY OF TECLISTAMAB, A B‐CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Author(s) -
Popat R,
Usmani S,
Garfall A,
Donk N,
Nahi H,
SanMiguel J,
Oriol A,
Nooka A,
Martin T,
Rosinol L,
Chari A,
Karlin L,
Benboubker L,
Mateos M,
Bahlis N,
Moreau P,
Besemer B,
MartínezLópez J,
Sidana S,
Pei L,
Trancucci D,
Verona R,
Girgis S,
Olyslager Y,
Jaffe M,
Uhlar C,
Stephenson T,
Van Rampelbergh R,
Banerjee A,
Goldberg J,
Kobos R,
Krishnan A
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000829596.42296.29
Subject(s) - medicine , tolerability , multiple myeloma , cytokine release syndrome , adverse effect , oncology , clinical endpoint , cancer , gastroenterology , chimeric antigen receptor , clinical trial , immunotherapy